This study examined the utility of serum neurofilament light chain (sNfL) and glial fibrillary
acidic protein (sGFAP) as biomarkers in primary progressive multiple sclerosis in context
with clinical severity, progression, and treatment. Using a single-molecule array (Quanterix),
serum protein concentrations were measured from twenty-five participants semiannually for
five years. There was no association between levels of either biomarker and disease
severity, disease duration, or treatment group. Enrollment sNfL level was not associated with …